Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

NEXT STORY
New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress
PREV STORY
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference

YONKERS, N.Y., Nov. 15, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

author_avatar
NASDAQ Market News

Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           

author_avatar
NASDAQ Market News

Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD

BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical ...

author_avatar
NASDAQ Market News